- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Vor Biopharma reports Q2 results | 2 | Seeking Alpha | ||
| Di | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 1.272 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Vor Biopharma Inc. - 10-Q, Quarterly Report | 7 | SEC Filings | ||
| 03.08. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 07.07. | Vor Bio appoints David Zaccardelli to board of directors | 1 | Investing.com | ||
| 07.07. | Vor Bio beruft erfahrenen Pharma-Manager David Zaccardelli in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 07.07. | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | 238 | GlobeNewswire (Europe) | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| 07.07. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 08.06. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China | 1 | GlobeNewswire (USA) | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China | 585 | GlobeNewswire (Europe) | First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published... ► Artikel lesen | |
| 01.06. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Vor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | 982 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| 13.05. | Vor Biopharma reports Q1 results | 3 | Seeking Alpha | ||
| 13.05. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade | 5 | Zacks | ||
| 04.05. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 15.04. | H.C. Wainwright senkt Kursziel für Vor Biopharma auf 31 US-Dollar | 1 | Investing.com Deutsch | ||
| 15.04. | H.C. Wainwright lowers Vor Biopharma price target to $31 | 1 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,429 | -0,61 % | VALNEVA SE: Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates | Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,585 | -0,66 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| EDITAS MEDICINE | 2,510 | +1,62 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,135 | -0,87 % | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
Strategic partnering remains a key priority, with multiple strategic discussions progressing, including... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,860 | -0,38 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | ||
| GERON | 1,332 | -1,99 % | GERON CORP - 8-K, Current Report | ||
| TRAWS PHARMA | 0,600 | +12,59 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| VERASTEM | 5,828 | -3,61 % | Mizuho lowers Verastem stock price target on valuation to $13 | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Pad Gopal, Chief Financial Officer and Interim Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), announces that Mr. Pad Gopal has provided... ► Artikel lesen | |
| UNIQURE | 39,150 | -0,13 % | uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update | ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~
~ Topline four-year data from the Phase I/II study of AMT-130 expected... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,390 | +1,36 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates | First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient... ► Artikel lesen | |
| ZAI LAB LTD ADR | 22,200 | 0,00 % | ZAI LAB (09688): NOTICE OF AUDIT COMMITTEE ACTION | ||
| TRINITY BIOTECH | 11,760 | +3,80 % | Trinity Biotech plc: Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology | - Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,820 | +1,66 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| ARCTURUS THERAPEUTICS | 7,925 | +4,28 % | Arcturus auf der 46. Jährlich Wachstumskonferenz von Canaccord Genuity: Starke Liquidität und bevorstehende Katalysatoren |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,970 (+4,34 %) liegt der Kurs bei 23,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.